Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NMBR | P28336 | 14/20 | 0.56 |
| ▸ | TACR1 | P25103 | 1/20 | 0.51 |
| ▸ | TACR3 | P29371 | 1/20 | 0.49 |
| ▸ | MMP2 | P08253 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | MMP8 | P22894 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18255297 | 0.89 | CTSL (0.54) | NMBRTACR1MAPT | |
| SCHEMBL16915248 | 0.89 | NMBR (0.58) | NMBRTACR1TACR3GAAMAPT | |
| SCHEMBL18251829 | 0.88 | NMBR (0.65) | NMBRTACR1MMP9MMP8GAA | |
| SCHEMBL18255298 | 0.87 | NMBR (0.51) | NMBRTACR1MMP2MMP8 | |
| SCHEMBL9088692 | 0.86 | NMBR (0.72) | NMBRTACR1TACR3GAAMAPT | |
| SCHEMBL6013894 | 0.82 | NMBR (0.61) | NMBRTACR1TACR3GAAMAPT | |
| SCHEMBL4930789 | 0.81 | NMBR (0.58) | NMBRTACR1TACR3MAPT | |
| SCHEMBL4930779 | 0.81 | NMBR (0.58) | NMBRTACR1TACR3MAPT | |
| SCHEMBL18251830 | 0.81 | NMBR (0.70) | NMBRTACR1TACR3MMP9MMP8 | |
| SCHEMBL6020259 | 0.81 | NMBR (0.58) | NMBRTACR1TACR3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | ALPHABETA AB (SE) | 2016-11-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160340387-A1 | NOVEL LIGANDS FOR PREVENTION OF NEUROTOXICITY OF THE ALZHEIMER'S DISEASE RELATED AMYLOID-BETA PEPTIDE | APP, BACE1, PSEN1 | NMBR 92/4885TACR1 370/4885TACR3 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.